The cell therapy company TiGenix NV has appointed two executives from the Grifols group to its board of directors following Grifols decision to become a strategic investor in the company. The first appointee is Dirk Büscher, chief executive of Gri-Cel SA, a wholly-owned Grifols subsidiary. Based in Spain, Grifols is the world’s third largest producer of plasma-derived products. Dr Büscher obtained his PhD in biology and immunology from the University of Hannover in Germany and worked in a post-doctoral capacity in stem cell research at the Salk Institute in La Jolla, California, US. The second appointee is José Terencio, chief operating officer of Gri-Cel. Dr Terencio obtained his PhD in CNS pharmacology from the University of Barcelona in Spain.
TiGenix announced the appointments on 5 December 2013.
Copyright 2013 Evernow Publishing Ltd